tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

CABA Stock Latest News

Cabaletta Bio’s treatment of myasthenia gravis granted FDA orphan designation
The FlyCabaletta Bio’s treatment of myasthenia gravis granted FDA orphan designation
3d ago
CABA
Cabaletta Bio: Promising Progress and Strategic Timelines Drive Buy Rating
PremiumRatings
Cabaletta Bio: Promising Progress and Strategic Timelines Drive Buy Rating
1M ago
CABA
Cabaletta Bio Advances in Autoimmune Therapy Development
PremiumCompany Announcements
Cabaletta Bio Advances in Autoimmune Therapy Development
1M ago
CABA
Cabaletta Bio: Strong Financial Position and Strategic Clinical Advancements Justify Buy Rating
PremiumRatings
Cabaletta Bio: Strong Financial Position and Strategic Clinical Advancements Justify Buy Rating
1M ago
CABA
Cabaletta Bio: Promising Clinical Progress and Strategic Advancements Drive Buy Rating
PremiumRatings
Cabaletta Bio: Promising Clinical Progress and Strategic Advancements Drive Buy Rating
1M ago
CABA
Cabaletta Bio reports Q3 EPS (44c), consensus (46c)
PremiumThe FlyCabaletta Bio reports Q3 EPS (44c), consensus (46c)
1M ago
CABA
Cabaletta Bio sees cash runway into 2H26
Premium
The Fly
Cabaletta Bio sees cash runway into 2H26
1M ago
CABA
Is CABA a Buy, Before Earnings?
Premium
Pre-Earnings
Is CABA a Buy, Before Earnings?
1M ago
CABA
Cabaletta Bio price target raised to $30 from $15 at Cantor Fitzgerald
PremiumThe Fly
Cabaletta Bio price target raised to $30 from $15 at Cantor Fitzgerald
1M ago
CABA
Cabaletta Bio Updates on CD19-CAR T Therapy Progress
PremiumCompany Announcements
Cabaletta Bio Updates on CD19-CAR T Therapy Progress
1M ago
8K
CABA
Cabaletta Bio’s Promising Clinical Advances and Strategic Plans Earn Buy Rating from Michael Ulz
PremiumRatings
Cabaletta Bio’s Promising Clinical Advances and Strategic Plans Earn Buy Rating from Michael Ulz
2M ago
CABA
Cabaletta Bio’s Innovative Myopathy Study: A Potential Game-Changer?
PremiumCompany Announcements
Cabaletta Bio’s Innovative Myopathy Study: A Potential Game-Changer?
2M ago
CABA
Cabaletta Bio’s Promising SLE Study: A Potential Game-Changer?
PremiumCompany AnnouncementsCabaletta Bio’s Promising SLE Study: A Potential Game-Changer?
2M ago
CABA
Cabaletta Bio’s Promising Study on CABA-201 for Systemic Sclerosis: A Market Perspective
Premium
Company Announcements
Cabaletta Bio’s Promising Study on CABA-201 for Systemic Sclerosis: A Market Perspective
2M ago
CABA
Cabaletta Bio’s RESET-MG Study: A Potential Game-Changer for Myasthenia Gravis Treatment
Premium
Company Announcements
Cabaletta Bio’s RESET-MG Study: A Potential Game-Changer for Myasthenia Gravis Treatment
2M ago
CABA
Cabaletta Bio’s Promising Clinical Trial Results Lead to Buy Rating
PremiumRatings
Cabaletta Bio’s Promising Clinical Trial Results Lead to Buy Rating
2M ago
CABA
Cabaletta Bio’s RESET-MS Study: A New Frontier in Multiple Sclerosis Treatment
PremiumCompany Announcements
Cabaletta Bio’s RESET-MS Study: A New Frontier in Multiple Sclerosis Treatment
2M ago
CABA
Cabaletta Bio’s Innovative Study on Pemphigus Vulgaris: A Potential Game-Changer
PremiumCompany Announcements
Cabaletta Bio’s Innovative Study on Pemphigus Vulgaris: A Potential Game-Changer
2M ago
CABA
Cabaletta Bio’s Innovative Dosing Strategy and Clinical Advancements Earn a Buy Rating
PremiumRatings
Cabaletta Bio’s Innovative Dosing Strategy and Clinical Advancements Earn a Buy Rating
2M ago
CABA
Cabaletta Bio Announces Positive Clinical Data Updates
PremiumCompany AnnouncementsCabaletta Bio Announces Positive Clinical Data Updates
2M ago
8K
CABA
Cabaletta Bio presents data, development updates for Rese-cel
Premium
The Fly
Cabaletta Bio presents data, development updates for Rese-cel
2M ago
CABA
Cabaletta Bio management to meet with Cantor Fitzgerald
Premium
The Fly
Cabaletta Bio management to meet with Cantor Fitzgerald
2M ago
CABA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >